Oscar Health (NYSE:OSCR – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $5.75 price target on the stock. Zacks Investment Research‘s target price suggests a potential upside of 20.29% from the stock’s previous close.
According to Zacks, “Oscar Health Inc. is a digital health-insurance company. Oscar Health Inc. is based in New York. “
OSCR has been the subject of several other research reports. Bank of America downgraded Oscar Health from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $12.00 to $6.00 in a report on Thursday. Morgan Stanley decreased their price objective on Oscar Health from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Monday, March 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Oscar Health presently has a consensus rating of “Hold” and a consensus target price of $10.04.
Oscar Health (NYSE:OSCR – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.04. Oscar Health had a negative return on equity of 37.23% and a negative net margin of 22.93%. During the same quarter in the prior year, the business earned ($0.98) earnings per share. On average, equities research analysts anticipate that Oscar Health will post -2.54 earnings per share for the current year.
In other Oscar Health news, CFO Richard Scott Blackley sold 19,204 shares of the business’s stock in a transaction on Tuesday, March 8th. The stock was sold at an average price of $7.33, for a total value of $140,765.32. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Alessandrea C. Quane sold 11,638 shares of the business’s stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $8.30, for a total value of $96,595.40. The disclosure for this sale can be found here. Insiders have sold 40,557 shares of company stock valued at $304,575 in the last quarter.
A number of hedge funds have recently bought and sold shares of OSCR. Psagot Value Holdings Ltd. Israel lifted its position in shares of Oscar Health by 210.3% during the 4th quarter. Psagot Value Holdings Ltd. Israel now owns 2,371 shares of the company’s stock valued at $4,518,000 after buying an additional 1,607 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Oscar Health by 1.4% during the 4th quarter. Deutsche Bank AG now owns 121,153 shares of the company’s stock valued at $951,000 after buying an additional 1,653 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in shares of Oscar Health by 116.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,924 shares of the company’s stock valued at $30,000 after buying an additional 2,114 shares during the last quarter. Aquire Wealth Advisors LLC purchased a new position in shares of Oscar Health during the 4th quarter valued at $34,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Oscar Health by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 193,504 shares of the company’s stock valued at $1,930,000 after buying an additional 4,801 shares during the last quarter. 98.65% of the stock is currently owned by institutional investors and hedge funds.
Oscar Health Company Profile (Get Rating)
Oscar Health, Inc provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients.
- Get a free copy of the StockNews.com research report on Oscar Health (OSCR)
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.